Evolus (EOLS)
(Delayed Data from NSDQ)
$16.46 USD
+1.19 (7.79%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $16.01 -0.45 (-2.73%) 6:56 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.46 USD
+1.19 (7.79%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $16.01 -0.45 (-2.73%) 6:56 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Zacks News
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
What's in Store for Flexible Solutions (FSI) in Q2 Earnings?
by Zacks Equity Research
Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.
Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong performances from Loulo-Gounkoto and Veladero likely to drive Barrick's (GOLD) Q2 results.
Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?
by Zacks Equity Research
Advance Auto Parts (AAP) Q2 results to gain on footprint expansion. However, high capital expenditures and tough competition make surprise prediction difficult.
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Will Evolus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Evolus.
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Allergan Up As Analyst Statement Sparks Business Split Rumors
by Zacks Equity Research
Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.
Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.
Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
by Zacks Equity Research
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
by Zacks Equity Research
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
by Zacks Equity Research
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Allergan Responds to Investor's Call for CEO/Chair Role Split
by Zacks Equity Research
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
by Zacks Equity Research
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.